We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · May 24, 2021

Efficacy and Safety of Nivo/Ipi for Advanced or Metastatic Renal Cell Carcinoma

Current Oncology (Toronto, Ont.)


Additional Info

Current Oncology (Toronto, Ont.)
Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
Curr Oncol 2021 Apr 03;28(2)1402-1411, K Iinuma, K Kameyama, K Kawada, S Fujimoto, K Takagi, S Nagai, H Ito, T Ishida, M Kawase, K Kawase, C Nakai, D Kato, M Takai, K Nakane, T Koie

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading